RT Journal Article
SR Electronic
T1 Impact of growth hormone on sleep disordered breathing in infants with Prader-Willi syndrome
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP P3273
VO 44
IS Suppl 58
A1 Tom Carlisle
A1 Emma Carruthers
A1 Felicity Gray
A1 Mark Rosenthal
A1 Nicola Bridges
A1 Hui-Leng Tan
YR 2014
UL http://erj.ersjournals.com/content/44/Suppl_58/P3273.abstract
AB IntroductionGrowth hormone (GH) is a recommended treatment for Prader-Willi Syndrome (PWS), however, it has been implicated in cases of sudden death, with the first few weeks after starting GH therapy the most vulnerable time for developing significant sleep disordered breathing (SDB). UK guidelines recommend sleep studies to detect the severity of SDB pre and post GH initiation. This study investigates the effects of GH on respiratory sleep parameters in PWS infants.Methods14 patients were identified from hospital records aged <2yrs, who had pre and post GH respiratory polygraphy (RP) studies since February 2009. Studies were scored as per 2007 AASM guidelines. Statistical analysis was by the paired-sample Wilcoxon test.ResultsThere were no significant differences in any of the RP values pre and post GH initiation (Table 1).DiscussionThe SDB events were predominantly central rather than obstructive events. In contrast to some previous studies, no infant in our cohort developed obstructive sleep apnoea necessitating cessation of GH. This may be because they are a younger cohort and longer follow up is required. GH therapy appears safe in PWS infants.Table 1. Demographics and RP parameters pre and post growth hormone initiation.Data are presented as median (interquartile range). Abbreviations: GH, growth hormone; AHI, apnoea-hypopnoea index; AI, apnoea index; ODI, oxygen desaturation index.